UC Irvine Researchers Lead the Charge Against Looming Antibiotic Resistance Crisis
Table of Contents
A new generation of infectious disease specialists at UC irvine is pioneering innovative strategies to combat the growing threat of antibiotic resistance, a challenge the World Health Organization warns could surpass cancer as a leading cause of death by 2050.
The specter of untreatable infections looms large, driving researchers like Shruti K. Gohil, MD, MPH, and Erlinda (“Chulie”) Ulloa, MD, to the forefront of the battle against antimicrobial resistance. Recognized for their groundbreaking work with the Fall 2025 Rising Star Award from the UC Irvine School of Medicine, these specialists are not only identifying the problem but actively developing solutions to safeguard patient care.
The Rising Tide of resistance: A Global Health Emergency
The overuse of antibiotics, especially within hospital settings, is a critical driver of antibiotic resistance, according to one leading expert.”Over the last two years, my work has centered on changing the way we use antibiotics,” she explained. The consequences are dire, with the World Health Organization projecting that deaths attributable to antibiotic resistance could exceed those from cancer within the next two decades.
Dr. Ulloa’s focus centers on the particularly vulnerable pediatric population.”When a child comes to us with an infection that is resistant to every antibiotic we’ve tried, families are terrified and clinicians feel helpless,” she stated. Her research aims to expand treatment options,improve existing antibiotic efficacy,and accelerate diagnostic processes.
Gohil’s “Sea Change” in Antibiotic Prescribing
Dr. Gohil is advocating for a essential shift in how antibiotics are prescribed, a “sea change” needed to avert the predicted crisis. Her work centers on reducing the inappropriate use of broad-spectrum antibiotics, which contribute significantly to resistance and can have detrimental side effects.
Through a series of four randomized controlled trials – collectively known as the INSPIRE trials – Dr. Gohil evaluated a tool designed to help physicians better assess which patients truly require broad-spectrum antibiotics. “We created prompts in the electronic health record system to see if we could influence physician behavior related to choosing broad-spectrum antibiotics,” she explained.
Currently, the standard practice frequently enough involves initiating treatment with broad-spectrum antibiotics for common infections like pneumonia, urinary tract infections, and skin infections. This approach, though, leads to 40% to 50% of patients receiving these powerful drugs unnecessarily, increasing their risk of antibiotic resistance, kidney toxicity, liver toxicity, and disruption of the gut microbiome.
The results of the INSPIRE trials are promising: the tool reduced broad-spectrum antibiotic overuse by up to 35%, without compromising patient safety. “We were able to address fears of under-treating a patient, because the saf
